ArticleCancers2022

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Jing-Houng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.